JP2009542228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542228A5 JP2009542228A5 JP2009518632A JP2009518632A JP2009542228A5 JP 2009542228 A5 JP2009542228 A5 JP 2009542228A5 JP 2009518632 A JP2009518632 A JP 2009518632A JP 2009518632 A JP2009518632 A JP 2009518632A JP 2009542228 A5 JP2009542228 A5 JP 2009542228A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- recombinase
- chimeric
- site
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000018120 Recombinases Human genes 0.000 claims 77
- 108010091086 Recombinases Proteins 0.000 claims 77
- 238000005215 recombination Methods 0.000 claims 32
- 230000006798 recombination Effects 0.000 claims 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 24
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 22
- 239000011701 zinc Substances 0.000 claims 22
- 229910052725 zinc Inorganic materials 0.000 claims 22
- 239000013612 plasmid Substances 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 15
- 150000007523 nucleic acids Chemical group 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 12
- 230000003197 catalytic effect Effects 0.000 claims 11
- 108020004414 DNA Proteins 0.000 claims 7
- 230000003115 biocidal effect Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 108010052160 Site-specific recombinase Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000010354 integration Effects 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 102100029212 Putative tetratricopeptide repeat protein 41 Human genes 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000002457 bidirectional effect Effects 0.000 claims 2
- 230000002759 chromosomal effect Effects 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 102220638483 Protein PML_K65R_mutation Human genes 0.000 claims 1
- 101710193739 Protein RecA Proteins 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 230000037429 base substitution Effects 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000002939 deleterious effect Effects 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 102220198221 rs1057519921 Human genes 0.000 claims 1
- 102220119961 rs116089237 Human genes 0.000 claims 1
- 102220052286 rs182351748 Human genes 0.000 claims 1
- 102220032813 rs367543161 Human genes 0.000 claims 1
- 102200046998 rs62645894 Human genes 0.000 claims 1
- 102220093344 rs749571694 Human genes 0.000 claims 1
- 102200015709 rs766602837 Human genes 0.000 claims 1
- 102220018846 rs80358505 Human genes 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81890806P | 2006-07-05 | 2006-07-05 | |
| PCT/US2007/072869 WO2008006028A2 (en) | 2006-07-05 | 2007-07-05 | Chimeric zinc finger recombinases optimized for catalysis by directed evolution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542228A JP2009542228A (ja) | 2009-12-03 |
| JP2009542228A5 true JP2009542228A5 (https=) | 2010-08-26 |
Family
ID=38895472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518632A Withdrawn JP2009542228A (ja) | 2006-07-05 | 2007-07-05 | 定方向進化による触媒作用のために最適化されたキメラジンクフィンガーリコンビナーゼ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8685687B2 (https=) |
| EP (1) | EP2046806A4 (https=) |
| JP (1) | JP2009542228A (https=) |
| KR (1) | KR20090031938A (https=) |
| CN (1) | CN101484462A (https=) |
| AU (1) | AU2007269048A1 (https=) |
| CA (1) | CA2667974A1 (https=) |
| WO (1) | WO2008006028A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| MY160435A (en) * | 2008-06-12 | 2017-03-15 | Univ Putra Malaysia | A novel antiviral peptide against avian influenza virus h9n2 |
| WO2010042894A1 (en) * | 2008-10-09 | 2010-04-15 | The Regents Of The University Of California | NOVEL NUCLEIC ACID CONSTRUCTS CONTAINING ORTHOGONAL SITE SELECTIVE RECOMBINASES (OSSRs) |
| GB2467167B (en) * | 2009-01-26 | 2013-09-11 | Algentech Sas | Gene targeting in plants |
| WO2011017315A2 (en) | 2009-08-03 | 2011-02-10 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| US20130005590A1 (en) | 2011-06-06 | 2013-01-03 | The Regents Of The University Of California | Synthetic biology tools |
| WO2013163628A2 (en) * | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9738879B2 (en) | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
| HK1210192A1 (en) | 2012-07-19 | 2016-04-15 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| KR102357105B1 (ko) * | 2012-09-04 | 2022-02-08 | 더 스크립스 리서치 인스티튜트 | 표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들 |
| US10793867B2 (en) * | 2013-03-15 | 2020-10-06 | Monsanto Technology, Llc | Methods for targeted transgene-integration using custom site-specific DNA recombinases |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| RU2016116253A (ru) | 2013-09-27 | 2017-11-01 | Кодексис, Инк. | Автоматизированный скрининг вариантов фермента |
| BR112016006284B1 (pt) | 2013-09-27 | 2022-07-26 | Codexis, Inc | Método implementado por computador, produto de programa de computador, e, sistema de computador |
| JP6303195B2 (ja) * | 2013-11-20 | 2018-04-04 | 国立研究開発法人産業技術総合研究所 | 細菌による機能的外来タンパク質の製造方法 |
| CA2940322C (en) | 2014-02-21 | 2021-05-18 | President And Fellows Of Harvard College | De novo design of allosteric proteins |
| US11319555B2 (en) | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| CN104789555A (zh) * | 2015-04-29 | 2015-07-22 | 江南大学 | 一种基于合成单链dna文库进化基因表达调控元件的方法 |
| AR105776A1 (es) | 2015-08-21 | 2017-11-08 | Monsanto Technology Llc | Recombinación mejorada de loci genómicos |
| WO2017035416A2 (en) | 2015-08-25 | 2017-03-02 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| CN106011162A (zh) * | 2016-01-27 | 2016-10-12 | 浙江大学 | 大肠杆菌细胞内原位进化目标蛋白质的新方法 |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| EP3717505A4 (en) | 2017-12-01 | 2021-12-01 | Encoded Therapeutics, Inc. | GENENICALLY MODIFIED DNA-BINDING PROTEINS |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| CN109979591B (zh) * | 2019-03-12 | 2021-01-01 | 众安信息技术服务有限公司 | 一种基于图神经网络分析斑块进展因子的方法及装置 |
| PL3976798T3 (pl) * | 2019-05-29 | 2026-04-07 | Encoded Therapeutics, Inc. | Kompozycje i sposoby selektywnej regulacji genów |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| CN110868598B (zh) * | 2019-10-17 | 2021-06-22 | 上海交通大学 | 基于对抗生成网络的视频内容替换方法及系统 |
| US20210130828A1 (en) * | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Gin recombinase variants |
| CN121693564A (zh) | 2023-06-26 | 2026-03-17 | 夏威夷大学 | 进化的整合酶和其用于基因组编辑的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1303930A (zh) * | 1999-10-27 | 2001-07-18 | 上海博容基因开发有限公司 | 一种新的多肽——锌指蛋白57和编码这种多肽的多核苷酸 |
| GB0222229D0 (en) * | 2002-09-25 | 2002-10-30 | Univ Glasgow | Mutant recombinases |
| AU2005240091B2 (en) * | 2004-04-30 | 2011-12-15 | Poetic Genetics, Llc | Hybrid recombinases for genome manipulation |
| US7470777B2 (en) * | 2004-12-22 | 2008-12-30 | Iowa State University Research Foundation, Inc. | Compositions and methods related to modified retroviral vectors for restricted, site specific integration |
-
2007
- 2007-07-05 US US12/309,096 patent/US8685687B2/en not_active Expired - Fee Related
- 2007-07-05 AU AU2007269048A patent/AU2007269048A1/en not_active Abandoned
- 2007-07-05 WO PCT/US2007/072869 patent/WO2008006028A2/en not_active Ceased
- 2007-07-05 KR KR1020097002444A patent/KR20090031938A/ko not_active Withdrawn
- 2007-07-05 CA CA002667974A patent/CA2667974A1/en not_active Abandoned
- 2007-07-05 EP EP07799328A patent/EP2046806A4/en not_active Withdrawn
- 2007-07-05 CN CNA2007800254608A patent/CN101484462A/zh active Pending
- 2007-07-05 JP JP2009518632A patent/JP2009542228A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542228A5 (https=) | ||
| KR101817482B1 (ko) | 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정 | |
| CA3009727A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| US7608434B2 (en) | Mutated Tn5 transposase proteins and the use thereof | |
| Haas et al. | The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion | |
| CN104080462B (zh) | 用于修饰预定的靶核酸序列的组合物和方法 | |
| CA3131284C (en) | Compositions for linking dna-binding domains and cleavage domains | |
| AU740336B2 (en) | Heteroduplex mutational vectors and use thereof in bacteria | |
| EP3750999B1 (en) | Chimeric polypeptides having targeted binding specificity | |
| WO2017215648A1 (zh) | 基因敲除方法 | |
| WO2019239361A1 (en) | Method for sequence insertion using crispr | |
| US20250243512A1 (en) | Serine recombinase systems for site-specific gene editing | |
| CA3163087A1 (en) | System and method for activating gene expression | |
| JP2000287687A (ja) | プラスミドベクター | |
| KR102151064B1 (ko) | 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법 | |
| KR20190122596A (ko) | 염기 교정용 유전자 구조체, 이를 포함하는 벡터 및 이를 이용한 염기 교정 방법 | |
| WO1996040882A1 (en) | Artificial restriction endonuclease | |
| JP2022519308A (ja) | その中の核酸分子を差次的にメチル化するように操作されたミニサークル産生細菌 | |
| JP2009537130A (ja) | Ｍｏｓ−１トランスポゾンの高活性組換え誘導体の転移のためのシステム | |
| IL322974A (en) | CRISPR Systems Type 5, Class 2 | |
| US8318155B2 (en) | Nucleic acid cleaving agent | |
| KR102567576B1 (ko) | 표적 특이성이 향상된 신규한 Cas9 단백질 변이체 및 이의 용도 | |
| CN120092083A (zh) | 包含Cas蛋白和细菌毒素的融合蛋白及其用途 | |
| KR20190037167A (ko) | 혈액응고인자 viii 유전자 역위 보정능의 유전자 가위 시스템으로 구성된 혈우병 치료용 조성물 | |
| CA2957441C (en) | Genome editing using campylobacter jejuni crispr/cas system-derived rgen |